Dear Reader,

In the current issue we are pleased to present a Review in the section *HPV/Health Economics* dealing with cost-effectiveness analyses of vaccinating males against HPV (Jiang, p. 2285).

Four articles in the category *Licensed Vaccines*, look at genetic characteristics of *Neisseria meningitides* serogroup B strains carried by adolescents (Esposito, p. 2296), persistence of antibodies in adolescents after immunization with 4CMenB meningococcal serogroup B vaccine (Santolaya, p. 2304), safety and immunogenicity of *Haemophilus influenza* type *b* conjugate vaccines in Chinese infants (Shi, p. 2311), and vaccination for typhoid fever in Sub-Saharan Africa (Arya, p. 2316).

Multiple papers fall into the category *Novel Vaccines*, including three studies on dengue vaccine development looking at the persistence of Th1/Tc1 responses after tetravalent dengue vaccination (Harenberg, p. 2317), immune responses in mice induced by vaccination with DENV-2 recombinant proteins (Garcia-Machorro, p. 2326), and immunogenicity of photo-inactivated dengue virus in mice (Raviprakash, p. 2336). Two papers deal with purification (Curti, p. 2342) as well as biophysical and formulation studies (Cheng, p. 2351) of the extracellular domain of the *Schistosoma mansoni* TSP-2 recombinant protein, a lead vaccine candidate antigen for human intestinal schistosomiasis. Anthrax vaccine development is the topic of two papers in this track: biophysical characterization and immunogenicity studies of the candidate anthrax toxin subunit vaccine dominant negative inhibitor (Iyer, p. 2362), and in vitro and in vivo activities of recombinant anthrax protective antigen co-expressed with thioredoxin in E. coli (Ma, p. 2371). Papers on a trivalent vaccine comprising H5N1/EV71/JEV antigens (Lin, p. 2378), a low-toxic site-directed mutant of Clostridium perfringens ∑-toxin as a potential candidate vaccine against enterotoxemia (Li, p. 2386), and strategies for vaccine development against group A Streptococcus (Good, p. 2393) complete this section.

Three papers related to *Rotavirus* include a regulatory agency inquiry into potential porcine circovirus type 1 in the human rotavirus vaccine Rotarix (Dubin, p. 2398), a study of rotavirus-specific antibodies in children with acute gastroenteritis and children vaccinated with an attenuated human rotavirus vaccine (Herrera, p. 2409), as well as a commentary on how to overcome perceptions of financial barriers to rotavirus vaccine introduction in Asia (Nelson, p. 2418).

The section *Immunotherapy* features two papers on long-term survival and outcomes of patients given *Mybacterium vaccae* for metastatic malignant melanoma (Cananzi, p. 2427), and multi-therapeutic potential of autoantibodies induced by immune complexes trapped on follicular dendritic cells (El Shikh, p. 2434). A commentary on *Immunotherapy/HIV* discusses dendritic-cell-based therapeutic vaccines for HIV (Garcia, p. 2445).

Two papers on *Influenza* deal with evaluation of seasonal influenza vaccine effectiveness (Falchi, p. 2453), and safety, immunogenicity and tolerability of three different influenza vaccines in older adults (Scheifele, p. 2460). The section on *Hepatitis* features a study on the immunogenicity and safety of hepatitis E vaccine in healthy hepatitis B surface antigen-positive adults (Wu, p. 2474), and a case report of acute hepatitis A in an elderly patient after care worker travel to high endemicity country (Aasheim, p. 2480).

Finally, one paper on *Vaccine Acceptance/HPV* investigates social media microblogs as an HPV vaccination forum (Zhang, p. 2483), and one paper in the category *Patents* identifies factors that result in obviousness rulings for certain biotech patents (Lin, p. 2490).

As always, our monthly *News, Policy & Profiles* (*NP&P*) section provides you with a selection of the latest news in the field of vaccines and immunotherapeutics. In our *NP&P* track we also regularly present companies and organizations related to vaccines and immunotherapy, and we are pleased to feature the Swiss biotech company VAXIMM in the current issue. VAXIMM develops active anti-angiogenic immunotherapies for cancer patients, and Drs Klaus Breiner, Executive Chairman, and Heinz Lubenau, General Manager of VAXIMM, have kindly agreed to answer our questions. If you would like to see your company/organization featured in a future issue of *HV&I*, simply contact Eva Riedmann (eva\@landesbioscience.com). Furthermore, our *NP&P* section accepts commentaries on timely, interesting and controversial topics in the field of vaccines and/or immunotherapy. Your ideas for our *NP&P* track are always welcome.

Finally, we want to draw your attention to several popular web site features, which are usuable on all electronic devices, such as mobile phones and tablets, an RSS feed to see the latest published papers, and a *HV&I*facebook account for daily updates.

Sincerely,

Ronald Ellis, PhD

Editor-in-Chief

Eva M Riedmann, PhD

Acquisitions Editor
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